Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Revolution Medicines's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2025 it was $0. The highest annual figure on record is $50.04M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $11.58M | -67.3% |
| FY2022 | Dec 31, 2022 | $35.38M | +20.4% |
| FY2021 | Dec 31, 2021 | $29.39M | -31.6% |
| FY2020 | Dec 31, 2020 | $42.98M | -14.1% |
| FY2019 | Dec 31, 2019 | $50.04M | +148.2% |
| FY2018 | Dec 31, 2018 | $20.17M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $742.00K | -95.2% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.82M | -58.1% |
| Q1 FY2023 | Mar 31, 2023 | $7.01M | -7.4% |
| Q4 FY2022 | Dec 31, 2022 | $15.33M | +62.1% |
| Q3 FY2022 | Sep 30, 2022 | $3.36M | +204.8% |
| Q2 FY2022 | Jun 30, 2022 | $9.12M | +4.8% |
| Q1 FY2022 | Mar 31, 2022 | $7.58M | -25.2% |
| Q4 FY2021 | Dec 31, 2021 | $9.46M | +8.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.10M | -91.3% |
| Q2 FY2021 | Jun 30, 2021 | $8.70M | -13.2% |
| Q1 FY2021 | Mar 31, 2021 | $10.13M | -12.3% |
| Q4 FY2020 | Dec 31, 2020 | $8.75M | -27.6% |
| Q3 FY2020 | Sep 30, 2020 | $12.66M | +1.2% |
| Q2 FY2020 | Jun 30, 2020 | $10.03M | -18.4% |
| Q1 FY2020 | Mar 31, 2020 | $11.55M | -12.3% |
| Q4 FY2019 | Dec 31, 2019 | $12.09M | – |
| Q3 FY2019 | Sep 30, 2019 | $12.51M | – |
| Q2 FY2019 | Jun 30, 2019 | $12.28M | – |
| Q1 FY2019 | Mar 31, 2019 | $13.17M | – |